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NormalArp2/3 complex activation in platelets lacking WASp
Herve ´ Falet, Karin M. Hoffmeister, Ralph Neujahr, and John H. Hartwig
Arp2/3 complex is believed to induce de
novo nucleation of actin ﬁlaments at the
edge of motile cells downstream of WASp
family proteins. In this study, the signal-
ing pathways leading to Arp2/3 complex
activation, actin assembly, and shape
change were investigated in platelets iso-
lated from patients with Wiskott-Aldrich
Syndrome (WAS), that is, who lack WASp,
and in WASp-deﬁcient mouse platelets.
WASp-deﬁcient human and mouse plate-
lets elaborate ﬁlopodia, spread lamellae,
and assemble actin, identical to control
WASp-expressing platelets. Human plate-
lets contain 2 MArp2/3 complex, or 8600
molecules/cell. Arp2/3 complex redistrib-
utes to the edge of the lamellae and to the
Triton X-100–insoluble actin cytoskeleton
ofactivatedWASp-deﬁcientplatelets.Fur-
thermore, the C-terminal CA domain of
N-WASp, which sequesters Arp2/3 com-
plex, inhibits by half the actin nucleation
capacity of octylglucoside-permeabilized
and activated WAS platelets, similar to its
effect in WASp-expressing cells. Along
with WASp, platelets express WAVE-2 as
a physiologic activator ofArp2/3 complex
and a small amount of N-WASp. Taken
together, our ﬁndings show that platelets
activate Arp2/3 complex, assemble actin,
and change shape in the absence of
WASp, indicating a more specialized role
for WASp in these cells. (Blood. 2002;100:
2113-2122)
© 2002 by TheAmerican Society of Hematology
Introduction
Arp2/3 complex is believed to induce de novo nucleation of actin
ﬁlaments at the edge of motile cells.This complex, originally found
in Acanthamoeba castellanii, consists of 2 actin-related proteins,
Arp2 and Arp3, and 5 novel proteins, p41-, p34-, p21-, p20-, and
p16-Arc.1,2 Arp2/3 complex initiates the actin-based motility of
intracellular parasites such as Listeria monocytogenes and Shigella
ﬂexneri,3-5 branches actin ﬁlaments in vitro,6,7 and localizes at the
leading edge of crawling cells such as carcinoma cells and Xenopus
laevis keratocytes.8,9
The actin nucleation activity of Arp2/3 complex can be initiated by
WASp family proteins, 5 of which are expressed in mammals: WASp,
N-WASp, and WAVE-1, -2, and -3. WASp is expressed only in
hematopoieticcells,10notablyinmonocytes,lymphocytes,andplatelets,
whereas N-WASp is widely expressed.11 WAVE-1 (also called Scar)
was ﬁrst identiﬁed in Dictyostelium discoideum, then in vertebrates,12,13
and2homologues,WAVE-2and-3,weresubsequentlycloned.14WASp
and N-WASp are thought to activate Arp2/3 complex–mediated actin
nucleation activity to induce ﬁlopodia formation downstream of the
small guanosine triphosphatase (GTPase) Cdc42,11,15-19 whereas
WAVE-1, -2, and -3 are believed to orchestrate lamellae spreading
downstream of Rac.20 Recently, cortactin and Abp1 (or drebrin) have
also been added to the list of proteins that can activateArp2/3 complex
in mammalian cells.21-25
In vitro observations have elucidated the biochemical and
structural mechanisms by which WASp family proteins activate
Arp2/3 complex. The conserved C-terminal VCAdomain of WASp
and N-WASp binds and brings together actin monomers and
Arp2/3 complex to stimulate its actin nucleation activity, whereas
the CA domain alone sequesters and inhibits Arp2/3 complex.26-28
However, WASp and N-WASp are unable to activate Arp2/3
complexuntilsignalingmoleculessuchasCdc42andpolyphospho-
inostides (ppIs) release intramolecular inhibitory interactions to
expose the VCA domain.29,30 Listeria ActA resembles the VCA
domain of WASp proteins and activatesArp2/3 complex with some
similarity, whereas Shigella IcsA recruits endogenous N-WASp
from the host cell.31
Mutations in the WASP gene encoding WASp in humans results in
Wiskott-Aldrich Syndrome (WAS), a severe inherited X-linked reces-
sive hematopoietic disorder that is characterized by thrombocytopenia,
immunodeﬁciency, and eczema.10 WAS platelets have short circulation
times and are generally smaller, a phenotype that is partially reversed by
splenectomy.32,33 Importantly, all described mutations in the WASP gene
havebeenshowntoleadtothecompleteabsenceofWASpexpressionin
platelets.34,35 In this study, aspects of the signaling pathways leading to
Arp2/3 complex activation and actin assembly were investigated in
human WAS platelets and WASp-deﬁcient mouse platelets. Consistent
with previous observations,36,37 WASp-deﬁcient human and mouse
platelets activate Arp2/3 complex and redistribute it to the cell cortex,
and elaborate ﬁlopodia, spread lamellae, and assemble actin normally
when activated. Thus, WASp is unnecessary for a robust actin assembly
reaction, suggesting a more specialized role forWASp in platelets.
Patients, materials, and methods
Patients
Patients were diagnosed with WAS based on male sex, thrombocytopenia
with small platelets, immunodeﬁciency, and eczema, and identiﬁcation of a
mutation on their WASP gene. All patients were examined after splenec-
tomy and have platelet counts and sizes close to normal.Their platelets lack
WASp (Figure 9) and have normal discoid shape while circulating (data not
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infections, but no eczema. His WASP gene has a G1305 deletion in exon 10,
and his B and T cells express a truncated form of WASp at 5% to 20% of
normal level. The phenotype of patient P39 is moderate, with a history of
infections and mild eczema. His WASP gene has a G3Amutation in intron
6 at position 5. Full-length WASp is expressed at 5% to 20% of normal
level in his T cells but is absent in his B cells. Patient P32 presents a mild
phenotype diagnosed as X-linked thrombocytopenia. His WASP gene has a
G2913A mutation in exon 2, and his B and T cells express 5% to 20% of
full-length WASp.
Approval was obtained from the institutional review boards of both
Brigham and Women’s Hospital and the Center for Blood Research
(Harvard Medical School), and informed consent was approved according
to the Declaration of Helsinki.
Animals and reagents
The WASp-deﬁcient mice were provided by Drs Catherine T. Yan, Scott B.
Snapper, and Frederick W. Alt (Center for Blood Research, Harvard
Medical School, Boston, MA).38 The collagen-related peptide (CRP; amino
acids GCP*(GPP)10GCP*G, where P* means hydroxyproline), prepared
and cross-linked as previously described,39 was a gift from Drs Michael J.
Barnes, Richard W. Farndale, and C. Graham Knight (Department of
Biochemistry, University of Cambridge, Cambridge, England). The throm-
bin receptor PAR-1–activating peptide (TRAP; amino acids SFLLRNPND-
KYEPF) was purchased from Bachem Bioscience (King of Prussia, PA).
Arp2/3 complex, puriﬁed from human platelets as described,40 was a gift
from Dr Fumihiko Nakamura (Division of Hematology, Brigham and
Women’s Hospital, Boston, MA). Afﬁnity-puriﬁed rabbit polyclonal anti-
bodies directed against the last 19 amino acids of bovine Arp3 and the
amino acids 179-204 of human p34-Arc were a gift from Dr Matthew D.
Welch (Department of Molecular and Cell Biology, University of Califor-
nia, Berkeley, CA).3,41 Blocking experiments were performed using the
peptides to compete for Arp2/3 complex binding. Rabbit polyclonal
antibody B4, directed against the amino acids 224-238 of human WASp
(amino acids 226-240 of mouse WASp), was a gift from Drs Marco Lopez
and Tomas Kirchhausen (Center for Blood Research, Harvard Medical
School).42 Rabbit polyclonal antibody directed against full-length N-WASp
and the vector encoding GST-CA derived from N-WASp (amino acids
450-505) were a gift from Drs Le Ma, Rajat Rohatgi, and Marc W.
Kirschner (Department of Cell Biology, Harvard Medical School).26
GST-CA was expressed and puriﬁed as described.43 Goat polyclonal
antibody D-16, directed against an internal region of human WAVE-2, was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Positive
control for WAVE-2 included Jurkat T-cell lysate provided by the manufac-
turer. Rabbit skeletal muscle actin was isolated and labeled with pyrene as
described.44 All other reagents were also of the highest purity available
(Sigma, St Louis, MO, and Bio-Rad, Hercules, CA).
Platelet preparation
Blood from healthy volunteers and from WAS patients was collected in 0.1
volume of Aster-Jandl anticoagulant.44 Human platelet-rich plasma (PRP)
was prepared by centrifugation of the blood at 100g for 20 minutes. Blood
was collected from wild-type and WASp-deﬁcient mice by retro-orbital
plexus bleeding and anticoagulated in Aster-Jandl anticoagulant. Mouse
Figure 1. Platelets change shape normally in the
absence of WASp. Platelets isolated from a healthy
volunteer (A), WAS patient P39 (B), and wild-type (C) and
WASp-deﬁcient mice (D) were allowed to adhere on
CRP-coated glass coverslips. Images shown are cap-
tured 10 minutes after the initial adhesion and activation
reaction. Results shown are representative of the 3
patients studied. Filopodia are indicated by a white arrow.
Figure 2. Platelets assemble actin normally in the absence of WASp. (A)
Platelets isolated from a healthy human volunteer (F) and WAS patient P34 (E) were
activated with 25 M TRAP or 3 g/mL CRP. (B) Platelets from wild-type (F) and
WASp-deﬁcient (E) mice were activated with 1 U/mL thrombin or 3 g/mL CRP.
Platelets were ﬁxed with 3.4% formaldehyde, extracted with 0.1% Triton X-100 in
PHEM buffer containing 2 M FITC-phalloidin, and analyzed by FACS. Results
shown are expressed as the ratio between the ﬂuorescence of activated cells versus
resting cells and are representative of 3 to 4 experiments.
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followed by centrifugation of the supernatant and the buffy coat at 100g for
6 minutes. Human and mouse platelets were isolated from PRP using a
metrizamide gradient.45 Platelet concentration was adjusted to 3  108/mL,
and platelets were allowed to rest for 30 minutes at 37°C before use.
DIC light microscopy
Attachment and activation of platelets on CRP-coated surface were
followed by differential interference contrast (DIC) light microscopy.45
Coverslips were coated with 6 g/mL CRP in phosphate-buffered saline
(PBS) for 2 hours followed by extensive blocking with 0.5% bovine serum
albumin (BSA) in PBS. Petri dishes were maintained at 37°C with a
Harvard Apparatus (Holliston, MA) temperature controller TC-202. Plate-
letswereimagedonaZeissIM-35invertedmicroscopewithDICopticsand
 100 oil immersion objective. Images were captured with a Hamamatsu
C2400 CCD camera (Hamamatsu, Japan), processed for background
substraction and frame averaging with a Hamamatsu ARGUS image
processor and digitally recorded on Macintosh computer equipped with a
SCION frame grabber LG-3 (Frederick, MD).
Immunoﬂuorescence analysis
Platelets were centrifuged at 280g for 5 minutes onto poly-L-lysine–coated
coverslips, ﬁxed in 4% formaldehyde, permeabilized with 0.5% Triton X-100,
and blocked with 0.5% BSA in PBS. Arp2/3 complex sites were exposed by
treating the ﬁxed and blocked cytoskeletons with 0.1% sodium dodecyl sulfate
(SDS) for 1 minute. Specimens were washed in PBS and labeled with a mixture
of rabbit anti-Arp3 and anti–p34-Arc antibodies, each at 4 g/mL. Images were
obtained using a Zeiss Axiovert S100 microscope with a 100 oil immersion
objective. The peptides used to raise the antibodies3,41 were mixed with the
anti-Arp2/3 antibodies as controls (each at 50 g/mL) and blocked all detectable
antibody binding (Figure 5B).
Electron microscopy and immunogold labeling
Platelets isolated from WAS patients were attached to 5-mm round
poly-L-lysine–coated coverslips by centrifugation at 280g for 5 minutes at
room temperature. Resting platelets isolated from wild-type and WASp-
deﬁcient mice were attached to antiglycoprotein Ib (GPIb) antibody-
coated coverslips, and activated with 1 U/mL thrombin for 10 minutes at
37°C. Human and mouse platelet cytoskeletons were prepared by extraction
with 0.75% Triton X-100 in 60 mM PIPES (piperazine-N,N-bis-2-
ethanesulfonic acid), 25 mM HEPES (N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid), 10 mM EGTA (ethyleneglycoltetraacetic acid) and 2
mM MgCl2, pH 6.9, containing protease inhibitors and 2 M phalloidin
(PHEM buffer), as described.46 Extracted platelets were brieﬂy washed in
PHEM buffer and ﬁxed with 1% glutaraldehyde in PHEM buffer for 10
minutes. Unreacted aldehydes were blocked with 1 mg/mL sodium
borohydride in PHEM buffer for 1 minute. Arp2/3 complex sites were
exposed by treating the ﬁxed and blocked cytoskeletons with 0.1% SDS in
PHEM buffer for 1 minute. There was no speciﬁc labeling in the absence of
SDS (data not shown), showing the epitopes to be sequestered whenArp2/3
complex was not denatured. Cytoskeletons were washed with PHEM buffer
and incubated in 1% BSA in 150 mM NaCl, 20 mM Tris (TBS), pH 8.2.
Cytoskeletons were labeled with a mixture of rabbit anti-Arp3 and
anti–p34-Arc antibodies, each at 4 g/mL. Unbound antibodies were
washed away withTBS/1% BSA, pH 8.2, and cytoskeletons were incubated
with 10 nm colloidal gold coated with goat antirabbit IgG for 60 minutes.
Coverslips were washed thrice with TBS, then ﬁxed with 1% glutaralde-
hyde in PBS for 10 minutes. Controls included omitting the primary
antibodyandusingnonspeciﬁcrabbitantibodiesinsteadoftheafﬁnity-puriﬁed
anti-Arp3 and anti–p34-Arc antibodies. In the absence of speciﬁc primary
antibodies there was no detectable signal (data not shown). Cytoskeletons were
washed thrice with double-distilled water just before freezing. Samples were
rapid-frozen, freeze-dried, and rotary-shadowed with 1.2 nm tantalum-tungsten
followed by 2.5 nm carbon. Specimens were examined and photographed in a
JEOL 1200-EX electron microscope (Tokyo, Japan) using an accelerating
voltage of 100 kV.
SDS-PAGE and immunoblot analysis
Platelet proteins were lysed in SDS–polyacrylamide gel electrophoresis
(SDS-PAGE) sample buffer containing 5% -mercaptoethanol. After
boiling for 5 minutes, proteins were separated on 8% or 10% polyacryl-
amide gels and transferred onto an Immobilon-P membrane (Millipore,
Bedford, MA). Membranes were incubated overnight in 100 mM NaCl and
20 mM Tris, pH 7.4, containing 1% BSA, then probed with antibodies
directed against proteins of interest. Detection was performed with an
enhanced chemiluminescence system (Pierce, Rockford, IL).
For the Arp2/3 complex depletion, human platelets were lysed in 1%
Igepal CA-630 (also called Nonidet P-40), 50 mM Tris, pH 7.4, 150 mM
NaCl, 1 mM EGTA, 1 mM phenylmethylsulfonyl ﬂuoride (PMSF), 10
g/mLleupeptin, and 10 g/mLaprotinin, as described.47After centrifuga-
tion at 14 000g for 10 minutes at 4°C, the Igepal CA-630–soluble fraction
was passed twice over a GST-CAcolumn.40This procedure resulted in more
than 99% depletion of Arp2/3 complex (Figure 3B), as described for
neutrophils.48
Figure 3. PlateletArp2/3 complex level. (A) Increasing numbers of human platelets
were compared to known amounts of puriﬁed Arp2/3 complex by SDS-PAGE and
probed with a rabbit polyclonal antibody directed against the p34-Arc subunit of
Arp2/3 complex. The graph plots the density of the detected bands against the
platelet counts and the amount of puriﬁed Arp2/3 complex (inset) obtained from a
single immunoblot. The amount of Arp2/3 complex divided by the platelet count was
determined as the ratio between ﬁrst-order equation slopes best ﬁtting the data.
Human platelets contain 14.3  1021 mol Arp2/3 complex. (B) Lysates correspond-
ing to 7  106 platelets () were compared by anti-Arp3 immunoblot to their Arp2/3
complex-depleted counterparts complemented or not with 0.5 and 1  1013 mol
puriﬁed Arp2/3 complex (u). The amount of Arp2/3 complex was quantiﬁed by
densitometric analysis of the immunoblots.The histogram plots the percentage  SD
of the density relative to total from 3 independent assays.
Figure 4. Arp2/3 complex incorporation into the platelet cytoskeleton. (A) WAS
platelets were activated with 25 M TRAP (F)o r3g/mL CRP (E) for the indicated
times. (B) Wild-type (u) and WASp-deﬁcient () mouse platelets were activated with
1 U/mL thrombin for 1 minute. F-actin–associated Arp2/3 complex was collected by
centrifugation of Triton X-100 platelet lysates at 100 000g for 30 minutes at 4°C.
F-actin–associated and soluble fractions were displayed by SDS-PAGE, transferred
onto an Immobilon-P membrane, and probed with a rabbit polyclonal antibody
directed against Arp3. The amount of Arp2/3 complex in the cytoskeletal fraction
relative to total was quantiﬁed by densitometric analysis of the immunoblots. Values
are mean of 3 to 4 experiments  SD.
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Triton X-100 in PHEM buffer. Filamentous actin (F-actin) was isolated by
centrifugation at 100 000g for 30 minutes at 4°C in a Beckman Optima TL
ultracentrifuge (Palo Alto, CA) using polycarbonate tubes and a TLA 100
rotor. Triton X-100–insoluble and –soluble fractions were resolved by
SDS-PAGE, as described above.
Measurement of platelet F-actin content and barbed-end
nuclei numbers
Resting or activated platelets were ﬁxed in 3.4% formaldehyde and permeabil-
ized with 0.1% Triton X-100 in PHEM buffer in the presence of 2 M
ﬂuorescein isothiocyanate (FITC)–phalloidin.45 Bound FITC-phalloidin
was quantitated by FACS analysis using a Becton Dickinson FACSCalibur
ﬂow cytometer (Franklin Lakes, NJ).Atotal of 10 000 events was analyzed
for each sample.
Platelets were activated and extracted with 0.1%Triton X-100 in PHEM
buffer44 or permeabilized with 0.25% octylglucoside (OG) in PHEM buffer
and activated.49 The OG-platelet suspension was mixed and the platelets
were allowed to extract for 30 seconds at 37°C. When required, GST-CA
was added prior to activation, as described.43 The polymerization rate assay
started by the addition of 185 L 100 mM KCl, 2 mM MgCl2, 0.5 mM
adenosine triphosphate (ATP), 0.1 mM EGTA, 0.5 mM dithiothreitol, and
10 mM Tris, pH 7.0, to 100 Lplatelet extract, and the subsequent addition
of 15 L2 0M monomeric pyrene-labeled rabbit skeletal muscle actin.
Pyrene-actin ﬂuorescence was recorded using a spectroﬂuorimeter LS50
(Perkin-Elmer Analytical Instruments, Norwalk, CT). Excitation and emis-
sion wavelengths were 366 and 386 nm, respectively. The number of
barbed-end nuclei was determined as described.49
Results
Platelets change shape normally in the absence of WASp
The morphology and organization of the actin cytoskeleton of
human WAS platelets and WASp-deﬁcient mouse platelets, acti-
vated on a CRP-coated surface, speciﬁc for the collagen receptor
Figure 5. Arp2/3 complex distribution in the cytoskeleton of active human platelets. Human platelets were activated by centrifugation onto poly-L-lysine–coated glass
coverslips, permeabilized with 0.5% Triton X-100 in PBS, and ﬁxed and treated with 0.1% SDS. The actin cytoskeleton is labeled with a mixture of afﬁnity-puriﬁed rabbit
polyclonal anti-Arp3 and anti–p34-Arc antibodies and TRITC-labeled goat antirabbit IgG (A). Anti-Arp2/3 complex staining concentrated at the cell periphery and at foci in the
center of the cytoskeletons. The peptides (50 g/mL) used to raise the antibodies were used mixed with the anti-Arp2/3 complex antibodies as controls and blocked all
detectable antibody binding (B). Human platelets were activated by centrifugation onto poly-L-lysine–coated glass coverslips, permeabilized with 0.75% Triton X-100 in PHEM
buffer, ﬁxed, and treated with 0.1% SDS (C). Cytoskeletons were labeled with a mixture of rabbit polyclonal anti-Arp3 and anti–p34-Arc antibodies followed by 10 nm colloidal
gold coated with goat antirabbit IgG (black spheres). Cytoskeletons were ﬁxed, washed into water, rapidly frozen, freeze-dried, and metal-coated. Immunogold recognizing
Arp2/3 complex densely labels spread lamellar regions (lm) of the active cytoskeletons. Some internal structures are also labeled (arrows). The tipso ft h eﬁlopodia are poorly
labeled (f). Note that the electron and light microscopy patterns are identical and that there are no ﬁlopodia labeled in panelA. Bars represent 5 m (A) and 200 nm (C).
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attachment and spreading process of WASp-deﬁcient human and
mouse platelets were identical to control platelets. Both WASp-
expressing and WASp-deﬁcient platelets generated ﬁlopodia and
lamellae when exposed to CRP-coated surface.
Platelets assemble actin normally in the absence of WASp
We addressed whether WASp expression is required for platelet
actin assembly. Platelets isolated from WAS patients increased
their F-actin content normally after ligation of the thrombin
receptor PAR-1 with 25 M TRAP or of the collagen receptor
GPVI with 3 g/mL CRP (Figure 2A), consistent with previous
observations.36,37Similarly,WASp-deﬁcientmouseplateletsshowed
no defects in actin assembly in response to 1 U/mLthrombin or to 3
g/mLCRP(Figure 2B).
Human platelets contain 2 M Arp2/3 complex
We determined the amount of Arp2/3 complex expressed in human
platelets. By densitometric analysis of immunoblots against the Arp3
and p34-Arc subunits ofArp2/3 complex, using puriﬁed plateletArp2/3
complex as a standard,40 we estimated that human platelets contain
14.3 1021 molArp2/3 complex, or 8600 molecules/cell (Figure 3A).
To verify that the presence of other platelet proteins in whole lysates
does not affect the Arp2/3 complex signal on immunoblots, puriﬁed
Arp2/3 complex was added back to platelet lysates depleted of Arp2/3
complex by sequential passages over a GST-CA column. GST-CA
removed more than 99% of Arp2/3 complex from the extract. Similar
intensity signals were obtained with lysates corresponding to 7 106
platelets and their depleted counterparts complemented with 1 1013
molArp2/3complex,asestimated(14.3 1021mol/platelet 7106
platelets; Figure 3B). Because the average platelet volume is 7 1015
L, human platelets contain 2 MArp2/3 complex.
Normal Arp2/3 complex redistribution in the actin cytoskeleton
of WASp-deﬁcient platelets
The redistribution of Arp2/3 complex to the actin cytoskeleton of
WASp-deﬁcient platelets was evaluated.As is always observed for
WASp-expressing platelets (H.F., K.M.H., R.N., et al, submitted
manuscript), Arp2/3 complex redistributed to the actin cytoskel-
eton of WASp-deﬁcient activated platelets. Thirty percent of the
total platelet Arp2/3 complex was associated with the Triton
X-100–insoluble actin cytoskeleton of resting platelets (Figure 4).
This amount increased to 80% after stimulation of human WAS
platelets with 25 MTRAPand 3 g/mLCRPor after activation of
WASp-deﬁcient mouse platelets with 1 U/mL thrombin, identical
to normal WASp-expressing platelets. WASp was always Triton
X-100 soluble in platelets maintained under nonaggregating condi-
tions (data not shown). WASp redistribution to the actin cytoskel-
eton requires platelet aggregation50 to cross-link the ﬁbrinogen
receptor IIb3, a condition that is not required forArp2/3 complex
redistribution, actin assembly, and shape change.
The Arp2/3 complex redistributes to the cell cortex of
spread platelets
Platelets spread over glass surfaces using large circumferential
lamellae, although some ﬁlopodia are extended.44 Fluorescence
Figure 6. Arp2/3 complex incorporation into the cytoskeleton of the active WAS platelet. Platelets isolated from WAS patient P50 were activated by centrifugation onto
poly-L-lysine–coated glass coverslips and permeabilized with 0.75% Triton X-100 in PHEM buffer. Cytoskeletons were labeled with a mixture of rabbit polyclonal anti-Arp3 and
anti–p34-Arc antibodies and 10 nm colloidal gold coated with goat antirabbit IgG. Cytoskeletons were ﬁxed, washed into water, rapidly frozen, freeze-dried, and metal- coated.
Bars represent 2 m (A) and 200 nm (B,C). Lm indicates lamellae; f, ﬁlopodia; arrows, foci of gold labeling.
Arp2/3 COMPLEXACTIVATION IN THEABSENCE OF WASp 2117 BLOOD, 15 SEPTEMBER 2002 VOLUME 100, NUMBER 6
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From Figure 7.Arp2/3 complex distribution in the active mouse platelet cytoskeleton. Wild-type (A) and WASp-deﬁcient (B) mouse platelets were activated by 1 U/mLthrombin
on anti-GPIb antibody-coated glass coverslips and permeabilized with 0.75% Triton X-100 in PHEM buffer. Cytoskeletons were labeled with a mixture of rabbit polyclonal
anti-Arp3 and anti–p34-Arc antibodies and 10 nm colloidal gold coated with goat antirabbit IgG. Cytoskeletons were ﬁxed, washed into water, rapidly frozen, freeze-dried, and
metal-coated. Bars represent 200 nm; lm indicates lamellae; f, ﬁlopodia; arrows, foci of gold labeling.
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formed using a mixture of 2 rabbit polyclonal antibodies
directed against the Arp3 and p34-Arc subunits of Arp2/3
complex followed by either tetrarhodamine isothiocyanate
(TRITC)–labeled antirabbit IgG or 10-nm colloidal gold par-
ticles coated with goat antirabbit IgG. In the light microscope,
Arp2/3 complex becomes concentrated at the periphery of the
active platelet (Figure 5A). Internal labeling is also found,
concentrated in a number of foci near the center of the
spread platelet.
Because 80% of total Arp2/3 complex is retained in the active
cytoskeleton, the localization of Arp2/3 complex was further
investigated in the electron microscope in labeled and freeze-dried
specimens (Figure 5C). Once again, in the electron microscope,
Arp2/3 complex redistributes into lamellae at the cell periphery and
is bound predominantly in the short actin ﬁlament networks found
in these regions (lm). As observed in the light microscope, Arp2/3
complex is also found to rigorously decorate certain dense struc-
tures within the cytoskeleton (arrows). One noticeable exception is
the tips of ﬁlopodia that are poorly labeled with anti-Arp2/3
complex immunogold (f). Actin ﬁlaments that enter, and become
bundled, in ﬁlopodia derive from ﬁlaments originating in the
cytoskeletal center. Because some Arp2/3 complex labeling is
observed throughout the cytoskeleton, as well as the foci of dense
labeling that are found internally, some ofArp2/3 complex may be
associated with the origins of ﬁlaments that eventually become
collected in the ﬁlopodia. Labeling of Arp2/3 complex was
completely dependent on adding denaturating compounds (SDS or
methanol) and was not observed in the absence of primary
antibodies or with nonspeciﬁc primary antibodies substituted (data
not shown).
Similar to normal platelets,WASp-deﬁcient platelets spread and
elaborate ﬁlopodia, ﬁngerlike extensions composed of long actin
ﬁbers, and robustly ﬁll the spaces between the ﬁlopodia with
lamellae composed of short actin ﬁlaments organized into dense
orthogonal networks (Figures 6 and 7). Arp2/3 complex redistrib-
utes normally to the cortex as WASp-deﬁcient human and mouse
platelets spread on glass, in identical fashion to that observed in the
control platelets. Once again, some labeling of densities in the
cytoskeletal center was observed and the bundles of actin ﬁlaments
composing ﬁlopodia were poorly decorated with anti-Arp2/3
complex immunogold.
Arp2/3 complex contributes to the actin nucleation
activity of WAS platelets
Figure 8A shows that platelets isolated from healthy human
volunteers and activated for 1 minute with 25 M TRAP or 3
g/mLCRPincrease their barbed-end nuclei content from 49  18
(mean  SD, n 	 4) per cell at rest to 509  22 and 326  48,
respectively. In resting human WAS platelets, 43  18 barbed-end
nuclei were detected per cell (n 	 3). This number increased to
471  67 and 348  44 after 1 minute of activation with TRAP
and CRP, respectively. Similarly, WASp-deﬁcient mouse platelets
showed no defects in barbed-end nuclei production in response to
stimulation (Figure 8B), increasing their barbed-end nuclei number
from 56  12 (mean  SD, n 	 4) per cell at rest to 408  45 after
1 minute of activation with 1 U/mLthrombin.
To further determine whether Arp2/3 complex participates in
the actin nucleation activity of WASp-deﬁcient platelets, the
C-terminal CA domain of N-WASp, which sequesters and inhibits
Arp2/3 complex,26 was added to WAS platelets permeabilzed with
OG (Figure 8C).TRAP(25 M) induced the exposure of 195  20
and 213  15 barbed-end nuclei/platelet (mean  SD, n 	 3) after
1 minute of activation in normal and WAS platelets, respectively,
compared to 42  15 and 41  8 at rest. GST-CA(3 M) inhibited
by approximately 50% barbed-end nuclei production in WAS
platelets (134  12) similar to its effect in WASp-expressing cells
(134  16).43 Thus, WASp expression is not required for activation
of Arp2/3 complex in platelets and Arp2/3 complex contributes
in 50% of the barbed-end nuclei in activated OG-permeabil-
ized platelets.
Platelet WASp family proteins
Because platelets change shape, assemble actin, and activate
Arp2/3 complex in the absence of WASp, the expression of other
WASp family proteins was investigated by immunoblot analysis in
control andWASp-deﬁcient platelets. Figure 9 conﬁrms that human
and mouse platelets express WASp as a protein of 64 kDa. WASp
was not detected in platelets isolated from WAS patients, as
described,34-37 nor in platelets isolated from WASp-deﬁcient mice.
Anti–N-WASp antibody recognized a faint polypeptide of slightly
higher molecular weight (66 kDa) in human platelets and cross-
reacted with WASp, as evidenced by the presence of the 64-kDa
band absent inWASp-deﬁcient human and mouse platelets.We and
others51 failed to detect N-WASp in human platelets using other
available antibodies (data not shown). Human and mouse platelets
express WAVE-2 as a protein of apparent 84 kDa. Expression of
WAVE-1 and -3 remains to be determined.
Figure 8. Contribution of Arp2/3 complex activity to the production of actin
ﬁlament barbed ends in WAS platelets. (A) Barbed-end counts were determined in
Triton X-100 lysates of normal (u) and WAS () platelets activated with 25 M TRAP
or 3 g/mL CRP for 1 minute using the pyrene-labeled actin assembly assay, as
indicated. (B) Barbed-end counts were determined in Triton X-100 lysates of
wild-type (u) and WASp-deﬁcient () mouse platelets activated with 1 U/mLthrombin
for 1 minute as above. (C) Platelet isolated from healthy volunteers (u) and from WAS
patients () were permeabilized with 0.25% OG in PHEM buffer. The number of
barbed ends in OG-permeabilized platelets was determined without any addition
(rest), after incubation with 25 M TRAP for 1 minute (TRAP), or after incubation with
GST-CA(3M) followed by TRAP (TRAPGST-CA).
Figure 9. Platelet WASp family proteins. Lysates corresponding to 5  106
platelets isolated from a healthy volunteer (normal), WAS patient P34 (WAS), and
wild-type (WT) and WASp-deﬁcient (WASp) mice were displayed by SDS-PAGE,
transferred onto an Immobilon-P membrane, and probed with speciﬁc antibodies
directed against WASp, N-WASp, and WAVE-2, as indicated. Results shown for the
WAS platelets are representative of the 3 patients studied.
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De novo nucleation of actin byArp2/3 complex is a widely recognized
mechanism for promoting barbed-end–directed actin ﬁlament assembly
associated with intracellular propulsion of microorganisms.This system
is also thought to be responsible for actin remodeling at the cell edge
during spreading, locomotion, and phagocytosis downstream of WASp
family proteins. Human platelets contain 2 M Arp2/3 complex, or
8600molecules/cell,approximatelyhalftheestimatedamountofWASp
(4.7 M).52 However, our ﬁndings, consistent with those of others,36,37
show that WASp-deﬁcient human and mouse platelets elaborate ﬁlopo-
dia, spread lamellae, and assemble actin, all indistinguishable from
WASp-expressing platelets. They also incorporateArp2/3 complex into
the actin cytoskeleton and redistribute it to the edge of the actin-rich
lamellae following activation, demonstrating that WASp expression is
not required for Arp2/3 complex translocation into the cortex. Human
platelets may also express a small amount of N-WASp, as recently
described.52 However, because recombinant N-WASp must be added to
lysates of human platelets before the motility of Escherichia coli
expressing Shigella IcsA initiates,51 there is insufﬁcient N-WASp to
have an important physiologic role in platelets.
WASp and N-WASp are thought to activate Arp2/3 complex
actin nucleation activity to induce ﬁlopodia formation downstream
of Cdc42 and ppIs, based on in vitro experiments and transfection
into cultured cells.11,16,17,26-28 WASp overexpression leads to forma-
tion of actin clusters in nonhematopoietic cultured cells,15 and
inducible recruitment of WASp to a membrane receptor triggers
actin polymerization that results in ﬁlopodia formation.18,19 How-
ever, endogenous WASp and N-WASp are not required for
ﬁlopodia formation in platelets, consistent with recent reports that
show ﬁlopodia formation and actin assembly to be independent of
WASp or N-WASp expression in stimulated ﬁbroblasts.53,54 Be-
sides platelets, WASp is expressed in macrophages, dendritic cells,
and T and B cells where its deﬁciency results in impaired
podosome formation, cell polarization, motility, and phagocyto-
sis.55-60 WASp may be involved in the formation of supramolecular
activation clusters or immunologic synapses, and Arp2/3 complex
activation by WASp may be singularly important in such systems
for these highly specialized actin polymerization responses. WASp
may also have more specialized functions in immune cells, such as
in transcriptional activation, proliferative responses, and cytokine
production,61,62 functions that are not shared by platelets.
Lamellipodial actin assembly is classically thought to be
regulated by the small GTPase Rac, rather than Cdc42.63,64 Arp2/3
complex localizes at the edge of the lamellae of platelets spread on
glass, as does Rac.65 Pathways leading toArp2/3 complex from Rac
include the WAVE proteins and the activation of phosphoinositide
(PI) kinases, particularly PI 5-kinases.49,66 WAVE proteins have
been shown to activate Arp2/3 complex downstream of Rac and
IRSp53.20 Human and mouse platelets express WAVE-2, consistent
with a recent report showing WAVE-2 to be widely expressed,
notably in hematopoietic cells.14 Another contributor may also be
cortactin. Cortactin is involved in the formation of lamellae
downstream of Rac and PAK in cultured cells, where it colocalizes
with Arp2/3 complex.67,68 Cortactin activates Arp2/3 complex21-23
and also redistributes to the cortex of spread platelets.69 Rac also
mediates the production of ppIs at the cytoplasmic surface of the
plasma membrane that recruits actin regulatory proteins and causes
the uncapping of the barbed ends of the actin ﬁlaments previously
severed by Ca-activated gelsolin in platelets.44,49 These ends,
once uncapped, are subsequently ampliﬁed by Arp2/3 complex to
drive actin assembly (H.F., K.M.H., R.N., et al, submitted manu-
script). Hence, Arp2/3 complex activity is potentiated by actin
ﬁlament barbed-end uncapping at the edge of the platelet lamellae.
Recently, the small GTPase Rho has also been shown to activate
and participate in the production of ppIs that regulate actin
assemblyrequiredforplateletshapechange.70Rhomediatedevents
are highlighted in Gq-deﬁcient platelets where Rac is not acti-
vated.71 Under normal conditions, Rac activation may predomi-
nate, explaining the C3-toxin insensitivity of the platelet actin
assembly response.72 Rac is by far a more potent activator of
barbed end exposure than Rho in vitro permeabilized platelets.49
Rho may also inactivate ADF/coﬁlin in platelets by mediating its
dephosphorylation.73,74 ADF/coﬁlin has been shown to regulate
Arp2/3 complex activity in vitro by producing actin ﬁlament
barbed ends,75 as does gelsolin in platelets. The roles of Rho and
ADF/coﬁlin in platelet lamellae spreading and Arp2/3 complex
activation are unknown.
In conclusion, our ﬁndings demonstrate that the actin assembly
system remains fully functional in platelets in the absence of
WASp, suggesting that proteins other than WASp, probably
WAVE-2 or cortactin or both, activate Arp2/3 complex in these
cells. The origin of the thrombocytopenia and the short platelet
circulation times associated with WAS remains unclear. WASp
appears to be required for normal platelet integrity. Thus, WASp
deﬁciency may affect the surface organization of platelets such that
clearance is accelerated.
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